Biogen Pays Cardiokine $50M In Deal On Hyponatremia Drug July 3, 2007 By Jim Shrine Cardiokine Inc. is getting $50 million up front in a potential $220 million deal with Biogen Idec Inc. covering the vasopressin receptor antagonist lixivaptan. (BioWorld Today)Read More
RSS